SOLANA BEACH, CALIFORNIA / ACCESS Newswire / August 4, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to ...
The Company Achieved 20% Comparable Sales Growth in the Fourth Quarter of 2025 at $10.4 Million Preliminary unaudited financial results demonstrated total revenue in the fourth quarter of 2025 of ...
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q2 2025 Earnings Call Transcript August 12, 2025 ClearPoint Neuro, Inc. misses on earnings expectations. Reported EPS is $-0.21 EPS, expectations were $-0.2.
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / September 25, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise ...
The Company Achieved 20% Comparable Sales Growth in the Fourth Quarter of 2025 at $10.4 Million SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 12, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results